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Summary Bladder cancer cells have been shown to secrete a variety of factors that are not related to cells of urothelial origin. The
histogenesis of these tumour developments is uncertain, and a variety of theories have been previously reported. In the present manuscript,
we identify the factors constitutively produced by a human bladder cancer cell line (KU-19-19) that was found to produce beta human
chorionic gonadotrophin (,B-hCG), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-
CSF), interleukin 1 a (IL-1a), interleukin 6 (IL-6) and interleukin 8 (IL-8). The cells were obtained from a case of metastatic carcinoma that was
originally diagnosed to be a grade 3 (WHO classification), invasive transitional cell carcinoma of the bladder. On microscopic observation, the
cultured cells exhibited an epithelial appearance with vacuole formation in their cytoplasm. Ultrastructural observations revealed relatively
marked microvilli and a tight junction. Significant amounts of P-hCG, G-CSF, GM-CSF, IL-1cc, IL-6 and IL-8 concentrations in the supernatant
from cultured cells were demonstrated by enzyme-linked immunosorbent assays, while the expression of mRNA of these marker proteins in
cancer cells was also significantly exhibited by reverse transcription polymerase chain reaction (RT-PCR). In addition, the expression of G-
CSF receptor and IL-6 receptor mRNA was also shown by RT-PCR. Xenograft transplantability using nude mice was observed in association
with the presence of severe neutrophilia in the peripheral blood. These results indicate that this cell line appears to be an effective model for
the study of transitional cell carcinoma of the bladder with multipotent differentiation potentials.
Keywords: human transitional cell carcinoma; cytokine expression; cytokine receptor expression; totipotential differentiation; beta human
chorionic gonadotrophin; haematopoietic growth factors
Bladder cancer cells have been shown to secrete a variety of
biological factors that do not appear to be of urothelial cell origin
(Russell et al, 1988a). Transitional carcinoma cells have been
studied biochemically and immunologically to define possible
prognostic indicators and/or to develop reagents for both diag-
nostic and therapeutic use. Several specific proteins have been
produced by bladder cancer cells, including alkaline phosphatase
(Benham et al, 1977), human chorionic gonadotrophin (hCG)
(Rosen et al, 1980), carcinoembrionic antigen (Hall et al, 1973),
fibrinolytic proteins (Kinjo et al, 1979), angiogenic factors
(Chodak and Summerhayes 1984) and prostaglandins (Droller et
al, 1979). Furthermore, a variety of granulocyte and macrophage
colony-stimulating factors (Welte et al, 1985; Zinzor et al, 1985)
have been produced in vitro. Similarly, the production of various
cytokines, including transforming growth factors (Heckl et al,
1984; Kaashoek et al, 1991) has also been demonstrated.
Basal epithelial cells have previously been shown to respond to
urinary epidermal growth factor, which is presumed to be ofrenal
origin (Messing et al, 1987). The receptors have been shown to
have a high affinity, and significantly large amounts have been
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shown to be expressed in invasive tumours (Neal et al, 1989;
Smith et al, 1989). Closer relationships have been examined
histopathologically, which has led to the identification of cellular
features of squamous and glandular differentiation (Russell
et al, 1988b,c). The ectopic expression of human chorionic
gonadotrophin, particularly free f-hCG, in patients with bladder
cancer is well recognized as being a common phenomenon (Iles et
al, 1991). Clinically, hCG expression by bladder cancer is also
associated with advanced disease (Dexeus et al, 1986) and radio-
resistance (Grawford et al, 1991).
At the same time, both granulocyte colony-stimulating factor
(G-CSF) and granulocyte-macrophage colony-stimulating factor
(GM-CSF) produced by non-haematopoietic malignant cells have
been reported to be capable of inducing a leukaemoid reaction in
the host through the intense stimulation of leucocyte production
(Welte et al, 1985; Demetri and Griffin, 1991; Wetzler et al, 1993;
Sato et al, 1994), and this phenomenon is most frequently associ-
ated with aggressive tumour cell growth and detrimental clinical
outcome (Sires et al, 1986).
The mechanisms and histogenesis that accompany ectopic
production of these specific marker proteins and cytokines still
remain to be clarified, however several theories have been proposed.
Thus, to shed further light on this compelling issue, the present
communication deals with our recent observation of a human
bladder cancer line that expresses multiple marker proteins,
including ,B-hCG, as well as a variety of haematopoietic growth
factors and cytokines.
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MATERIALS AND METHODS
Cell source
The cell line was derived from a 76-year-old male patient
presenting with a metastatic perineal mass resected from invasive
bladder cancer (transitional cell carcinoma, grade 3 according to
the World Health Organization system; Mostofi et al, 1973; pT3b),
who also demonstrated marked leucocytosis (peripheral blood
leucocyte count, 94 900 mm-3; serum G-CSF level, 103 pg ml-').
Four months after a cystectomy, the patient died of multiorgan
metastases generated by the cancer.
Tissue culture method
On a Petri dish containing cold cell culture medium (RPMI-1640,
Gibco) supplemented with 10% heat-inactivated fetal calf serum
(FCS, Gibco), the tumour tissue was trimmed to remove any
necrotic tissue. The tumour tissue was then minced into approxi-
mately 1-mm3 pieces, placed in a culture flask (Falcon, 25 cm2),
kept in 3.5 ml of growth medium (RPMI-1640 supplemented with
10% heat-inactivated FCS and streptomycin 100 ,tg ml-', Sigma)
and then cultured in a humidified atmosphere of 5% carbon
dioxide in air at 37°C.
The cells were then subcultured and maintained in 25-cm2
culture flasks, kept in 3.5 ml of cultured medium (RPMI-1640
supplemented with 10% heat-inactivated FCS and streptomycin
100 ,tg ml-') in a humidified atmosphere of 5% carbon dioxide in
air at 37°C. The culture medium was renewed every 2-3 days and,
when the cells reached confluent phase, the cells were harvested
by 0.25% trypsin with 0.1 mm EDTA; the cells were then seeded at
a split ratio of 5:1.
Cloning of the cells
To clarify the heterogeneity of the cells, the cloning of the cells
was carried out by the limit dilution method. Briefly, the cells at
passage number 20 were diluted in the previously described
culture medium and were then adjusted to a cell density ofapprox-
imately 20 cells per ml of suspension. Subsequently, 1 ml of the
cell suspension medium was seeded into the cell culture dishes
(35 mm in diameter, Falcon) and cultured. When the cells formed
colonies, each colony was scraped by a Cell Scraper (Falcon); the
colony was then seeded into a 25-cm2 tissue culture flask with
3.5 ml of the culture medium and then maintained under further
incubation in a humidified atmosphere of5% carbon dioxide in air
at 37°C. In addition, the cells at passage number 20 were subse-
quently cultured in the presence of different concentrations of
serum; and finally subcloned cells capable ofgrowth in serum-free
medium were obtained.
Growth characteristics and chromosome counts
The growth curves were established by seeding 5 x 104 cells onto
35-mm culture dishes. Triplicate dishes were harvested and
counted daily. To measure plating efficiency, 100 single cells
Table 1 The RT-PCR primer sequences, PCR conditions and the PCR product sizes
Primer sequences (product sizes) PCR conditions
1-Actin (801 bp)
F: 5'-GATATCGCCGCGTCGTCGTGGAC-3'
R: 5'-CAGGAAGGAAGGCTGGAAGAGTGC-3'
G-CSF (278 bp)
F: 5'-CTGTGTGCCACCTACAAG-3'
R: 5'-GCCATTCCCAGTTCTTCC-3'
GM-CSF (441 bp)
F: 5'-CTGGAGATGTGGCTGCAGAGCC-3'
R: 5'-TGCTGGGAGCCAGTCCAGGAGTGA-3'
L-1 a (421 bp)
F: 5'-GTCTCTGAATCAGAAATCCTTCTATC-3'
R: 5'-CATGTCAAATTTCACTGCTTCATCC-3'
IL-6 (628 bp)
F: 5'-ATGAACTCCTTCTCCACAAGCGC-3'
R: 5'-GAAGAGCCCTCAGGCTGGACTG-3'
IL-8 (306 bp)
F: 5'-GTAAACATGACTTCCAAGCT-3'
R: 5'-TTGAAGAGGGCTGAGAATGCATAA-3'
1-hCG (519 bp)
F: 5'-GACGCACCAAGGATGGAGATGTT-3'
R: 5'-TCCTCCCACAATAAAGGCTTCTC-3'
G-CSF receptor ax-chain (727 bp)
F: 5'-ACAGTCCTCACCCTGATGACCT-3'
R: 5'-TGCCTCTTAAAGGCCTGAGCTA-3'
GM-CSF receptor a-chain (621 bp)
F: 5'-TGACCAGCACCATGCTTCTCCT-3'
R: 5'-ACCAGCCCGAGAAATTGGCATCC-3'
IL-6 receptor a-chain (522 bp)
F: 5'-CGGAAGACAATGCCACTGTTCA-3'
R: 5'-AGCATCACTGTGTCATCCACGA-3'
(94°C 1 min, 650C 1 min, 720C 3 min, 20 cycles)
(940C 1 min, 500C 1 min, 40 cycles)
(94°C 30 s, 63°C 1 min, 43 cycles)
(950C 1 min, 600C 1 min, 35 cycles)
(94°C 1 min, 60°C 1 min, 720C 2 min, 40 cycles)
(940C 1 min, 630C 1 min, 40 cycles)
(940C 1 min, 630C 1 min, 720C 1 min, 40 cycles)
(940C 1 min, 650C 1 min, 720C 1 min, 35 cycles)
(94°C 1 min, 60°C 1 min, 720C 3 min, 45 cycles)
(940C 1 min, 600C 1 min, 720C 1 min, 45 cycles)
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were plated in triplicate on 60-mm dishes and, 14 days after cell
seeding, the dishes were then stained with Giemsa's solution
(Gibco). Colonies containing more than 50 cells were counted. For
chromosome observation, the cells at passage number 20 in expo-
nential growth were treated with 0.1 mg ml-' colcemid for 4 h.
All the cells were harvested, exposed to hypotonic treatment
(75 ,umol 1-1 potassium chloride) for 20 min and then fixed with
methanol-glacial acetic acid (3:1). Slide preparations of the cells
were airdried, stained with Giemsa's solution and then scored forthe
number ofchromosomes present in each ofthe metaphase cells.
Transplantation of KU-19-19 cells into nude mice
Six- to 8-week-old BALB/c athymic nude mice were maintained
in a pathogen-free environment. Tumour xenografts were grown
by the inoculation of approximately 1 x 106 cells per 0.1 ml in a
subcutaneous region on the back of the nude mice using a tuber-
culin syringe fitted with a 26-gauge needle. When the tumours
reached more than 2 cm in diameter, they were removed and trans-
planted aseptically into other nude mice subcutaneously on the
back. During the tumour development, tumour widths (a) and
lengths (b) were measured using micrometer callipers. The
tumour volume (V) was then estimated according to the formula
V = (a2 x b)l2 and expressed in cm3 (Ovejera et al, 1978).
Thus, the estimated tumour volume in xenografts did not exceed
10% ofthe host animal's normal body weight (27-35 g).
Preparation of samples from the KU-19-19
tumour-bearing nude mice
Blood and tissue samples from KU-19-19 tumour-bearing nude
mice were prepared to determine both the marker proteins and the
white blood cell counts. Blood samples were drawn via cardiac
puncture at the time of sacrifice. Serum samples obtained after
centrifugation were frozen at -80°C until tested in the enzyme-
linked immunosorbent assays (ELISAs). The tumours from the
nude mice were weighed, fixed with 10% formalin and embedded
in paraffin. KU-1 cells obtained from human bladder cancer
(Tachibana, 1982) were used as control cells. The KU-1 cells did
not express any cytokines. Thereafter, exactly the same animal
experiments were performed, and the peripheral blood counts and
concentrations of various cytokines and r-hCG were thus deter-
mined. These animal experiments were performed to clarify the
biological characteristics of the particular cells in vivo, and they
were approved by the Ethical Committee of the Keio University,
School of Medicine, through the review of the written animal
experiment protocol. Furthermore, the animal experiments were
performed strictly under UKCCR guidelines for the welfare of
animals in experimental neoplasia (Workman et al, 1988), and the
tumour was removed before exceeding 10% of the host animal's
normal body weight.
Histological examination
Each primary tumour and its xenograft developed in nude mice
were examined microscopically as well as immunohistochemically.
The tumours were fixed with 10% formalin, stained with haema-
toxylin-eosin (H&E) and were then microscopically observed.
Immunohistochemical staining was performed on the primary
tumour and the KU-19-19 xenograft developed in nude mice using
antibodies specific to G-CSF (R&S Science, mouse IgG monoclonal
.~~~~~~~V _l ek*
Figure 1 Microscopic observation of the cultured KU-19-19 cells in vitro. The
cultured KU-19-19 cells showed a cobblestone-like appearance.
Intracytoplasmic vacuoles were occasionally seen (Giemsa's staining, x200)
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Figure 2 The growth curve of the KU-19-19 cells in vitro. Doubling time and
plating efficiency at passage number 50 were 24.6 h and 35.16 ± 9.8%
respectively. Each value represents the mean + s.d. from three samples
antibody, 50-100 xdilution) and r-hCG (Daco, Carpinderial, mouse
IgG monoclonal antibody, 100-200 x dilution). CHO cells trans-
fected with human G-CSF cDNA (Shimamura et al, 1990) trans-
planted in severe combined immunodeficiency (SCID) mice that
had been fixed with 4% paraformaldehyde were used as a positive
control for G-CSF. Human choriocarcinoma cells from a testis
tumour were used as positive control forP-hCG (data not shown).
Electron microscopy
Cultured monolayer cells were fixed with I% glutaraldehyde for
I h and then post fixed in 2% osmium tetroxide also for I h.
Ultrathin sections were stained with uranyl acetate and lead citrate.
Measurements of various cytokines and P-hCG
concentrations in conditioned media
One millilitre ofcell suspension adjusted to 5 x 104 cells ml-' was
seeded onto 35-mm culture dishes. Whole supernatant from tripli-
cate dishes of each cell culture was collected and centrifuged
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Figure 3 Ku-19-19 xenografts in nude mice. KU-19-19 xenografts were
successfully maintained in nude mice. The in vivo xenografts doubling time
was approximately 7.2 days
daily; then the supernatants were stored at -80°C until the
measurement of various cytokine and f-hCG concentrations. The
various cytokines included interleukin-la and -1I (IL-ioc and
-1 3), interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 8 (IL-8),
tumour necrosis factor-o and -P (TNF-ox and -D), granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF) and ,B-hCG concentrations in
the culture-conditioned medium. The enzyme-linked immuno-
sorbent assay (ELISA) was used to measure both cytokine and (-
hCG concentrations.
Reverse transcription polymerase chain reaction
(RT-PCR)
The expressions of G-CSF, GM-CSF, IL-Io, IL-6, IL-8, P-hCG,
G-CSF receptor, GM-CSF receptor and IL-6 receptor mRNA were
determined using the reverse transcription polymerase chain reac-
tion (RT-PCR) method. Total RNA samples were purified from the
cultured cancer cells using the acid guanidine phenol chloroform
method (Chomozynski and Sacchi, 1987).
The respective RNAs (5 gg) were converted into cDNAs using
oligo (dT) primers and reverse transcriptase (code 8089SA, Gibco
BRL) and were diluted with water to obtain 100 gl of the cDNA
preparation. Five microlitres ofthis dilution was subjected to PCR.
All ofthe primer sequences used in the present study, PCR product
sizes and PCR conditions are listed in Table 1. All RT-PCR
primers designed should cross the exon-intron borders and are
commercially available (Takara Biomedical Center, Shiga, Japan).
To further confirm that the amplified products originated from
each respective cDNA, they were then subjected to appropriate
restriction enzyme digestions. Each cytokine and cytokine
receptor cDNA fragment were used as positive control. Size
markers were 4.3, 1.8, 1.1, 0.68, 0.38, 0.25 and 0.12 kb, except for
IL-lo. Size markers for IL-lot were 1.35, 1.08, 0.87, 0.60, 0.31,
0.28, 0.27, 0.23 and 0.19 kb (see Figure 8).
Figure 4 Histological examinations of the primary tumour. Microscopic
observation of the primary tumour demonstrated that the primary tumour
comprised transitional cell carcinoma with squamous metaplasia and papillary
invasive, grade 3 (A, x 100). The tumour specimens demonstrated immuno-
histochemically positive staining for f-hCG (B, x 200) and G-CSF (C, x 200)
Cytokine-neutralizing test
To demonstrate whether or not the presence of a specific antibody
for these cytokines would inhibit tumour cell proliferation, the cells
were incubated with or without serial concentrations ofneutralizing
antibodies, including anti-human G-CSF antibody (R&D Systems,
goat IgG, catalogue number AB-214-NA) and anti-human IL-6
(R&D Systems, mouse IgG, catalogue number MAB206).
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B
Figure 5 Histological examinations of the KU-19-19 xenografted tumour in nude mice. The KU-19-19 xenograft contained transitional cell structures with partly
squamous appearance (A, x 200). The xenografted tumour specimens demonstrated immunohistochemically positive staining for P-hCG (B, x 200) and G-CSF
(C, x 200). Different cells stained positively for G-CSF and P-hCG. The CHO cells transfected with human G-CSF cDNA and then transplanted in SCID mice as
a positive control for G-CSF showed strong positive staining, however only a very scanty patchy expression was noted (D, x 400)
The proliferative activities of these cells were determined using
the [3H]thymidine incorporation method. The serum-free subclone
cells (1 x 104) were incubated in 0.1 ml of the culture medium
without FCS in a 96-well microtitre tray (Nunc, Denmark). Each
antibody was added every 24 h for a total ofthree times to the cell
cultures with or without serial concentrations (ranging from 0 to
100 jig ml protein for anti-G-CSF antibody and 0-50 ,ug ml-
protein for anti-IL-6 antibody). Twenty-four hours after the final
antibody treatments, DNA synthesis in the cultures was deter-
mined by the addition of [methyl-3H] thymidine (Amersham, UK)
(0.6 jiCi per well; 1 Ci = 37 MBq) during a 4-h pulse. Cells were
harvested onto glass fibre filters and counted using a liquid scintil-
lation counter (LS 9800, Beckman Instruments, USA).
As a control for each antibody, 100 jig ml concentration of
goat IgG fraction for G-CSF antibody and 50 jig ml-' concentra-
tion ofmouse IgG fraction for IL-6 antibody were added in exactly
the same way as the antibody.
Measurement of G-CSF and 1-hCG concentration in
supernatants from cultured cells after retinoic acid
treatment and their growth activities estimated by flow
cytometric bromodeoxyuridine labelling
Approximately 3 x 106 cells were seeded in 25-cm2 culture flasks
with 5 ml ofculture medium, and various concentrations ofall-trains
retinoic acid (RA, Sigma) (final concentrations of 0, 10-, 10 and
10-1 M) were added to the culture medium; the cells were then subse-
quently cultured for 24 h. Next, the RA-treated cells were harvested,
and a cell suspension containing 3 x 104 cells ml was made using
culture medium, and 1 ml of the cell suspension was reseeded onto
24-well culture dishes. After culturing, the supematant of the
cultured medium was collected from each cell culture well every
24 h, and the concentrations of G-CSF and P-hCG in each cell
culture media were measured using the ELISA technique.
In addition, the same preparations were carried out exactly as
before and the cell growth activities were measured using the flow
cytometric bromodeoxyuridine incorporation assay method as
described previously (Tachibana et al, 1992). Briefly, 2 and 4 days
after the cell seeding (3 and 5 days after initial RA treatment),
bromodeoxyuridine (brdUrd) was added to each culture well
at a final concentration of S jig ml-', and then incubation was
continued for another I h. The cells were harvested with 0.25%
trypsin and I mM EDTA and were then washed twice. The cells
were subsequently stained with FITC-labelled anti-BrdUrd anti-
body and then were poststained with 0.5% propidium iodide. The
double-stained cells were analysed with an Epics Elite flow
cytometer (Coulter, Hialeah, FL, USA), and the labelling index
(LI, the number of cells stained with BrdUrd divided by the total
estimated cell count) was thus calculated.
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Statistical analysis
The unpaired t-test was used to determine the statistical differ-
ences. A P-value less than 0.05 was designated to be statistically
significant.
RESULTS
Establishment of the cell line
An outgrowth ofthe cells was seen on about the 20th day after the
primary culture of the metastatic perineal mass. The primary
cultures generated a monolayer culture within I month and were
subcultured at a split ratio of 1: 2. Subsequently, the cells were
- subcultured in greater split ratios and at decreasing time intervals.
~~*< ~- ~ ~'~'~- The cells were havested by 0.25% trypsin with 0.01 mmi EDTA,
and the split ratio was 1:10 every 5-7 days. The cell line was
~~ ~~~ ~~~ - ~~designated as KU-19-19 and has been propagated continuously by
4 serial passaging over the past year.
A total of 12 subcloned cell lines were subsequently established,
including a serum-free condition clone.
V Characteristics of KU-19-19
Fiew The cultured KU-19-19 cells showed a cobblestone-like appear-
ance. Intracytoplasmic vacuoles are occasionally seen (Figure 1).
J The growth curves are indicated in Figure 2. The doubling time
and plating efficiency at passage number 50 were 39.1 h and
35.16 ± 9.8% respectively (Figure 2).
KU-19-19 xenografts in nude mice
KU-19-19 xenografts were successfully maintained in nude mice.
The doubling time ofthe xenografts growing in vivo was approxi-
--_ s ./| mately 5.9 days (Figure 3). Serum concentrations ofG-CSF, GM-
__ 4g, CSF and 1-hCG were significantly elevated (2824.6 ± 267 pg ml-
~- for G-CSF, 48.8 ± 35.6 pg ml 'for GM-CSF and 158 ± 95 ng ml-'
for P-hCG) in the KU-19-19 tumour-bearing nude mice with
significant leucocytosis (ranging from 65 000 to 112 000 mm-3),
ion electron microscopic observation of the cultured KU- while the concentrations of these proteins in the control nude mice
)Itrastructural studies exhibited the presence ofabundant (KU-1-bearing mice) were at less than detectable levels and their
on ofjunctional complexes (A, x 8000; B, x 15 000) peripheral blood leucocyte count was 8945 ± 857 mm-3. The
Table 2 The concentrations of various cytokines and ,B-hCG in the serum of the patient and in the supernatants from
cultured cells estimated by the ELISA technique
Reference ranges Patient's serum Cultured media
G-CSF (pg ml-') 3.7-32.3 103 71 500
GM-CSF (pg ml-') < 2.00 58.8 2 010
IL-la (pg ml-') < 7.80 18.6 299
IL-2 (pgml-') < 12.5 ND ND
IL-6 (pg ml-') 0.221-4.62 21.1 604
IL-8 (pg ml-') < 10.0 18.8 14 500
TNF-a (pg ml-') < 7.80 ND ND
TNF-,B (pg ml-') < 0.567 15.6 ND
hCG (mlU ml-') < 1.0 ND ND
3-hCG (ng ml-') < 0.1 150 865
In the serum of the patient, 103 pg ml-' for G-CSF, 58.8 pg ml-' for GM-CSF, 18.6 pg ml-' for IL-la, 21.1 pg ml-' for IL-6,
18.8 pg ml-' for IL-8, 150 ng ml-' for P-hCG were detected, whereas IL-2, tumour necrosis factor-ac and -,B, and whole hCG
were not detectable. The concentrations in the supernatants of cultured cells at passage 50 of various cytokines and P-hCG
were 71 500 pg ml-' for G-CSF, 2010 pg ml-' for GM-CSF, 299 pg ml-' for IL-1a, 604 pg ml-' for IL-6, 14 500 pg ml-' for IL-8
and 865 ng ml-' for P-hCG. However, IL-2 and whole hCG were not detectable (ND).
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Figure 7 Chromosome analysis. In the cytogenetic analysis of KU-19-19 cells, 20 metaphases were counted. The number of chromosomes varied from 85 to
91 and the modal number was 88. The consistent structural abnormalities were add(4)(q31), add(8)(pl1), add(13)(pl1), add(14)(pl1), add(19)(q12) and marker
chromosomes
leucocyte count in KU-19-19-bearing mice was also significantly
higher than that in KU-I-bearing mice (P < 0.01).
Histological examinations
Histological examinations revealed that the primary tumour
comprised transitional cell carcinoma with squamous metaplasia,
which was papillary invasive and grade 3 (Figure 4A). The KU-
19-19 xenograft in nude mice also contained transitional cell struc-
tures, with some patterns indicative of squamous differentiation
(Figure 5A). Both the primary tumour specimen and xenograft
demonstrated immunohistochemically positive staining for G-CSF
andhCG-P. Cells positive for ,B-hCG and G-CSF were present in a
focal distribution ofprimary tumour specimens as shown in Figure
4B for P-hCG and Figure 4C for G-CSF. In addition, xenograft
specimens demonstrated positive staining for both f-hCG (Figure
5B) and for G-CSF (Figure 5C), and a similar pattern was also
observed for focal distribution. However, the cells that stained
positively for G-CSF and P-hCG were different. In contrast, the
stromal elements, such as capillary endothelial cells, granulocytes
and/or macrophages, were negative for G-CSF staining. The CHO
cells transfected with human G-CSF cDNA and transplanted in
SCID mice as a positive control for G-CSF showed strong positive
staining, however only a very scanty patchy expression was noted
(Figure SD).
Transmission electron microscopic study
An ultrastructural study exhibited the presence of abundant
microvilli with irregularly shaped nuclei (Figure 6A). Observations
made at higher magnifications clearly demonstrated the formation
ofjunctional complexes (Figure 6B).
Chromosome analysis
In the cytogenetic analysis of KU-19-19 cells, 20 metaphases were
counted. The number ofchromosomes varied from 85 to 91 and the
modal number was 88. The consistent structural abnormalities were
add(4)(q31), add(8)(pll), add(13)(pll), add(14)(pl1), add(19)(ql2)
and marker chromosomes (Figure 7).
The concentration of various cytokines and P-hCG in
the serum of the patient and in the supernatants from
cultured cell
The concentrations of various cytokines and f-hCG in the serum
of the patient were estimated using the ELISA technique and are
shown in Table 2. The G-CSF, GM-CSF, IL-lIx, IL-6, IL-8 and
P-hCG concentrations were higher than normal ranges.
The concentrations of various cytokines and 1-hCG in super-
natants from cultured cells are also listed in Table 2. Significantly
high concentrations of G-CSF, GM-CSF, IL-lot, IL-6, IL-8 and
P-hCG were thus detected.
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Figure 8 RT-PCR studies for detection of mRNA signals of various cytokines, cytokine receptors and P-hCG on the KU-19-19 cells. Expression of G-CSF,
GM-CSF, IL-la, IL-6, IL-8, fP-hCG mRNA were determined using the RT-PCR method. Also ascertained by RT-PCR were G-CSF receptor, GM-CSF receptor
and IL-6 receptor m-RNA. G-CSF, GM-CSF, IL-6, IL-8 and P-hCG mRNA signals were detected as shown in the Figure. Furthermore, G-CSF receptor and IL-6
receptor m-RNA were observed, while GM-CSF receptor m-RNA was not detectable. The size markers from the top of each panel were 4.3, 1.8, 1.1, 0.68, 0.38,
0.25 and 0.12 kb, except for IL-1 a. For IL-la, the size markers from the top were 1.35, 1.08, 0.87, 0.60, 0.31, 0.28, 0.23, 0.19, 0.12 and 0.07 kb. S, sample
from the KU-19-19 cells; M, marker; C, positive control cDNA fragment
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Table 3 Tritiated thymidine incorporation of cells after treatment with
anti-G-CSF and IL-6 neutralizing antibodies
[3H] Thymidine incorporation
(c.p.m. per well)
Anti-G-CSFantibody administration
Control 4132.2 ± 231.4
10 gg ml-' Anti-G-CSF antibody 3750.8 ± 178.8
50 ug ml-1 Anti-G-CSF antibody 3326.0 ± 246.2
200 gg ml-' Anti-G-CSF antibody 3166.7 ± 113.0
200 ig ml-' Goat IgG 4096.3 ± 245.2
Anti-IL-6 antibody administration
Control 3964.4 ± 147.3
1 ig ml-1 Anti-IL-6 antibody 4012.4 ± 195.0
10 ig ml-1 Anti-IL-6 antibody 4105.8 ± 258.5
50 ig ml-1 Anti-IL-6 antibody 4075.2 ± 158.4
50 jg mi-l Mouse IgG 4048.4 ± 252.4
The anti-G-CSF antibody-treated cells demonstrated a significantly lower
uptake than control cells and/or those treated with goat IgG (P < 0.05). The
anti-IL-6 antibody treatment did not elicit any significant changes in the
[3H]thymidine incorporation compared with controls.
RT-PCR study
RT-PCR was used to determine whether mRNA for G-CSF,
GM-CSF, IL-la, IL-6, IL-8 and f-hCG were expressed.
Also ascertained by RT-PCR were G-CSF receptor, GM-CSF
receptor and IL-6 receptor m-RNA. The messenger RNA signals
for G-CSF, GM-CSF, IL-lc, IL-6, IL-8 and f-hCG were observed
as shown in Figure 8A and B. Furthermore, G-CSF receptor and
IL-6 receptor m-RNA signals were observed, while no GM-CSF
receptor m-RNA was detectable (Figure 8B). Therefore, the
expressions of both mRNA for G-CSF and IL-6 and their
respective receptors were exhibited.
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Figure 9 Serial G-CSF and 3-hCG concentrations in supernatants from
cultured cells and their growth activities as estimated by the flow cytometric
bromodeoxyuridine labelling rates after subcloning. G-CSF and P-hCG
concentrations in each cloned cell cultured medium after culturing are shown
in the figure. The G-CSF minimum concentration was 115 ±58 pg ml-1 per
1 x 10-6 cells (clone 8) and the maximum was 7534 ± 335 pg ml-' per 1 x 106
cells (serum-free cells) (A). P-hCG minimum and maximum concentrations
were 272.2 ± 53.5 ng ml-' per 1 x 106 cells (clone 8) and 885 ± 127.4 ng ml-'
per 1 x 106 cells (non-cloned cells) respectively (B). Bromodeoxyuridine
incorporations 1 day after incubation were 59.1 ± 4.5%, 43.4 ± 4.8%,
59.9 ± 5.6% and 31.5 ± 4.8% for serum-free subline cells, non-cloning cells,
clone 1 and clone 8 respectively (C)
Serial G-CSF and ,-hCG concentrations in the
supernatants from cultured cells and their growth
activities as estimated by the flow cytometric
bromodeoxyuridine labelling rates in subclones
Cells from 12 subcloned lines were examined. The G-CSF and
P-hCG concentrations in the supematants from each cloned cell
culture after incubation are shown in Figure 9. The G-CSF
minimum concentration was 115 ± 58 pg ml (clone 8), while the
maximum was 7534 ± 335 pg ml-' (serum-free subline cells)
(Figure 9A). On the other hand, the P-hCG concentration
was 272.2 ± 53.5 ng ml-l at a minimum level (clone 8) and
885 ± 127.4 ng ml-l at a maximum level (non-cloning cells)
(Figure 9B). The bromodeoxyuridine incorporations at day after
incubation were 59.1 ± 4.5%, 43.4 ± 4.8%, 59.9 ± 5.6% and 31.5 +
4.8% for serum-free subline cells, non-cloning cells, clone and
clone 8 (Figure 9C) respectively.
Cytokine-neutralizing test
The [3H]thymidine incorporation of the cells following serial
concentrations of anti-G-CSF and anti-IL-6 antibody treatments
are listed in Table 3. The anti-G-CSF antibody-treated cells
demonstrated a significantly lower uptake than control cells or
cells administered with goat IgG (P < 0.05).
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Table 4 The concentrations of G-CSF and P-hCG in supernatants from cultured cells following retinoic acid treatments and their growth activities estimated by
flow cytometric bromodeoxyuridine (BrdUrd) labelling
G-CSF concentration (pg ml-') ,-hCG concentration (ng ml-') Bromodeoxyuridine Li (%)
Day 3 Day 5 Day 3 Day 5 Day 3 Day 5
Control 514+165 3235+155 21.5+5.5 134+21.7 25.8+2.1 17.7+2.3
RA (10-6M) 1557 + 235 6550 +265 69.9+ 23.1 378+ 14.9 23.1 + 2.2 14.9+ 3.1
RA (10-7 M) 1577 ± 169 4862+ 311 48.4 + 15.6 332+ 16.5 25.3+ 1.8 16.4 + 2.4
RA (10-8M) 970+ 166 4547 +255 54.4+ 10.5 301 + 11.8 24.6+ 2.1 14.8 + 2.6
G-CSF concentrations in supernatants from cultured cells 5 days after incubation were 6550 ± 155 pg ml 10 cells, 4862 + 311 pg ml-1 10-6 cells,
4547 ± 255 pg ml 10-6 cells and 3235 + 155 pg ml-' 10-- cells for retinoic acid concentrations of 10-6 M, 10-7 M, 10-8 M and control culture respectively. P-hCG
concentrations in supernatants 5 days after incubation were 378 ± 14.9 ng ml-'/106cells, 332 + 16.5 ng ml- 10- cells, 301 + 11.8 ng ml 10-6 cells and
134 + 21.7 ng ml- 10-- cells respectively. The differences in G-CSF and 1-hCG concentrations in control-cultured media and those in cells treated with retinoic
acid were statistically significantly different (P < 0.01). However, BrdUrd labelling rates demonstrated no significant differences between control cultures and
RA-treatment groups.
In contrast, the anti-IL-6 antibody treatments did not show any
significant changes in the [3H]thymidine incorporation compared
with the control cells.
The concentration of G-CSF and P-hCG in supernatants
from cultured cells after retinoic acid treatment and
their growth activities estimated by flow cytometric
bromodeoxyuridine (BrdUrd) labelling
The G-CSF and f-hCG concentrations in supernatants from
cultured cells after the addition of serial concentrations ofretinoic
acid treatments are listed in Table 4. G-CSF and P-hCG concentra-
tions in supernatants from 10-6 mol retinoic acid-treated cell
cultures 5 days after incubation were significantly higher than
those in supernatants from the control cell cultures (P < 0.01).
However, the BrdUrd incorporation rates demonstrated no signifi-
cant differences between the control cultures and the RA treatment
groups (Table 4).
DISCUSSION
Ample evidence has confirmed that certain cancer cells have the
capacity to produce multiple cytokines as growth factors and that
their receptors can act on the host cells surrounding a tumour as
well as on the tumour cells themselves. At least some of these
growth factors and their receptor expression may act in tumour
cell paracrine and/or atutocrine loop mechanisms, either by the
extracellular release of the growth factor or by some action of the
tumour itself(Nicolson, 1993).
The present study demonstrates that the established human
transitional cell carcinoma line constitutively produces significant
levels of multiple cytokines, such as haematopoietic growth
factors and f-hCG and also expresses multiple cytokine receptor
mRNAs for G-CSF and IL-6.
Various haematopoietic growth factors have been demonstrated
to be responsible for the in vitro and in vivo proliferation of bone
marrow progenitor cells into mature differentiated cells (Rowe and
Rapoport, 1992). However, it has been reported that IL-3, GM-
CSF and G-CSF stimulate proliferation and clonal growth of some
malignant haematopoietic cell types, including blasts of acute
leukaemias and lymphomas (Graffin et al, 1986; Tomonaga et al,
1986; Delwel et al, 1987; Kelleher et al, 1987; Vellenga et al,
1987) and that receptors for IL-3 and GM-CSF are present on
some leukaemic cell lines (Gasson et al, 1986; Park et al, 1986;
Mufson et al, 1987). GM-CSF and G-CSF were found to be
secreted in an autocrine fashion by clonogenic cells in patients
with acute myeloblastic leukaemia (Young and Griffin, 1986;
Oster et al, 1989).
Only limited data are available on the interaction of the
haematopoietic growth factors associated with non-haematopoietic
tumour tissue, even though such findings are important for clinical
studies presently in progress. Berdel et al (1988, 1989) reported
evidence suggesting that haematopoietic growth factors, such as IL-
3, GM-CSF andG-CSF, can stimulate the growth ofclonogenic cells
in some human non-haematopoietic malignant cell lines derived
from colorectal and bladder carcinomas in vitro. Similar data also
exist for IL-6, which exerts a growth-enhancing effect on non-
haematopoietic tumours and has also been observed in myelomas
(Kawano et al, 1988) and renal carcinoma cells (Miki et al, 1989). It
has also been reported that GM-CSF can stimulate the proliferation
of osteogenic sarcoma and breast cancer cell lines (Dedhar et al,
1988). The presence of functional GM-CSF receptors on small-cell
lung cancer cells has been reported (Baldwin et al, 1989).
In addition, a variety ofnon-haematopoietic malignant tumours,
including bladder carcinoma (Welte et al, 1985a; Souza et al,
1986; Serve et al, 1991; Grammatico et al, 1993), have been
confirmed to secrete G-CSF or GM-CSF (Wetzler et al, 1993) in
amounts large enough to cause a significant systemic haemato-
poietic effect. Therefore, the leukaemoid reaction is a well-known
paraneoplastic syndrome, which has been shown to arise from G-
CSF and/or GM-CSF production by cancer cells (Wetzler et al,
1993). Furthermore, the leukaemoid reaction has also been
observed clinically to appear at the advanced stage of cancer in
association with aggressive cell growth (Wetzler et al, 1993; Sato
et al, 1994). On the other hand, receptors for haematopoietic
growth factor have also been confirmed on the cell surface of
several non-haematopoietic cell types (Demetri and Griffin, 1991).
It is therefore deemed likely that haematopoietic growth factor
production and their receptor expressions exhibited by the cancer
cells thus play a crucial role in the paracrine and autocrine growth
loop by mediating the malignant progression of the non-
haematopoietic cancer cells. However, Serve et al (1991) tested
malignant cell lines from a broad range of human solid tumours
for their responsiveness to recombinant IL-6 or anti-human IL-6
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antibody in different assay systems and thus concluded that neither
the cytokine nor its neutralizing antibody demonstrated any major
interaction with the growth of non-haematopoietic human malig-
nant cell lines.
In the present study, it was demonstrated that the KU-19-19
cells do produce G-CSF and IL-6, and the expression of both of
their receptors was confirmed. Furthermore, G-CSF may show
autocrine growth in this cell line, because the anti-G-CSF antibody
administration clearly inhibited their cell growth. However, the
administration of anti-IL-6 antibody did not cause any changes in
their growth, even though the cells did express both IL-6 and IL-6
receptor. Thus, the true physiological significance of cytokine
and/or cytokine receptor expression on the surface of non-
haematopoietic cells remains unclear.
Meanwhile, the ectopic expression of hCG, and particularly the
free beta subunit hCG, by urothelial cancer cells has been recog-
nized as being a relatively common observation in tumours arising
from any part of the urogenital tract that features transitional cell
epithelium (Dexeus et al, 1986; Grawford et al, 1991; Iles and
Chard, 1991).
Clinically, the hCG expression by bladder cancer has also been
associated with advanced disease (Dexeus et al, 1986) and radio-
resistance (Grawford et al, 1991). Although the mechanisms that
regulate ectopic hCG production remain unknown, this phenom-
enon is thought to be an indicator of poor prognosis (Dexeus et al,
1986; Grawford et al, 1991).
Molecular genetic analysis of both P-hCG and G-CSF secreting
bladder tumour cell lines has shown that expression of these
proteins is not due to gene rearrangement or amplification and that
it is therefore probably due to an altered regulation ofgene expres-
sion (Iles and Chard, 1991). This theory also points to dedifferenti-
ation of the neoplastic bladder cells towards the characteristics
of the more totipotential stem cells of the trophoblast and/or
haematopoietic cells. However, the histogenesis oftransitional cell
carcinoma ofthe bladder expressing these specific marker proteins
remains uncertain.
To clarify this point, we treated these cells with retinoic acid as
it is a well-known potent cell differentation agent. We used
retinoic acid because this agent has already been applied in a clin-
ical setting to various diseases as a potent cell differentiation agent
(Hofmann, 1992; Bollg, 1994). As shown in the present study,
retinoic treatments of these particular cells elicited a significantly
increased G-CSF and 1-hCG production in the supematants from
the retinoic-treated cell cultures. If the ability of marker protein
production can be related to cell differentiation, the data may
suggest that the cell line can be differentiated by the agent.
However, to clarify the point, further similar studies are required
that include growth marker proteins, as well as the enhanced
and/or suppressed expression of other marker proteins, and
morphology.
Therefore, this established cell line is considered to be useful as
a model for understanding the nature of constitutive cytokine and
f-hCG production by transitional cell carcinoma, with regard to its
ability to demonstrate totipotential differentiation along with
tumour cell growth.
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